#CreativeDisruption: Latest & Future Technologies Impacting Life Sciences

#CreativeDisruption: Latest & Future Technologies Impacting Life Sciences

Overview

This thought-leader discussion is about technologies that are disrupting the life sciences and health innovation sectors today & tomorrow

About the Event


The Creative Disruption Forum is a high-level, interactive gathering built for executive leaders, senior researchers, startup founders, and biotech investors.

The Quantum Horizon Meets Real-World Science

We are witnessing a transformative shift in health innovation. While emerging paradigms like quantum computing promise to fundamentally redefine how we process biological complexity in the future, biopharma leaders today need actionable, deployable technologies to de-risk pipelines, accelerate drug discovery, and improve clinical outcomes now.

The Latest & Future Technologies Impacting Health Innovation and Life Sciences bridges the gap between tomorrow’s deep-tech horizons and today’s high-impact biological and computational breakthroughs. Hosted at ARC West London as a flagship London Life Sciences Week event, this interactive forum brings together biopharma executives, tech bio founders, investors, and academic leaders for unscripted, Chatham House Rules discussions on what is genuinely working, where the bottlenecks lie, and how to build scalable healthcare solutions.

From physical molecule-to-protein target engagement (such as CETSA® platforms) and human-relevant New Approach Methodologies (NAMs) to real-world AI applications in lead optimization, this event delivers an unfiltered "boots on the ground" look at modern translational science.

Why You Should Attend:

Ground Your Strategy in Real-World Tech: Move beyond theoretical hype to evaluate proven technologies transforming R&D pipelines today—including next-gen sequencing (NGS), advanced cell & gene therapies, and biophysical target-engagement assays.

De-Risk Your Clinical Pipeline: Discover how New Approach Methodologies (NAMs), organ-on-a-chip systems, and cellular shift assays are replacing legacy models, reducing Phase II/III failure rates, and delivering more efficacious molecules into the clinic.

Unfiltered "Boots on the Ground" Insights: Hear directly from SME CEOs and biopharma R&D directors on integrating AI into discovery pipelines—sharing candid case studies on what works, what has failed, and how to avoid costly missteps.

Connect Across the West Tech District: Engage directly with key anchors across West London’s innovation ecosystem, including Imperial College London, White City Innovation District, Paddington Life Sciences, Nexus, and ARC Group.

Actionable Peer-to-Peer Workshops: Participate in interactive afternoon breakout sessions designed to co-create practical strategies for scaling deep-tech venture navigating regulatory pathways for NAMs, and optimizing R&D data.


Who Should Attend:

  • Biopharma & Biotech Executives (CEOs, CSOs, CTOs, R&D Directors): Looking to de-risk discovery pipelines, adopt next-generation analytical platforms, and integrate computational tools effectively.
  • Tech Bio Founders & SME Leadership: Seeking real-world feedback on scaling ventures, securing investment, and overcoming wet-lab validation bottlenecks.
  • Venture Capitalists & Deep-Tech Investors: Eager to identify high-growth opportunities across both near-term biopharma technologies and long-term deep-tech frontiers.
  • Academic Researchers & Translational Scientists: Interested in commercializing spinouts and bridging the gap between basic research and clinical reality.
  • Clinical & Regulatory Leaders: Exploring FDA/MHRA roadmaps for NAM adoption, advanced diagnostics, and cell/gene therapy pathways.


Agenda

09:00 AM – 09:45 AM | Registration, Breakfast & Networking

Arrival, registration, and informal networking over breakfast.

09:45 AM – 10:00 AM | Welcome and sponsor thank yous

  • Welcome: Deb Spencer (ARC West London)
  • Opening Address: Prof Tony Sedgwick & Graham Combe

Draft Agenda

09:00 AM – 09:45 AM | Registration, Breakfast & Networking

Arrival, registration, and informal networking over breakfast.

09:45 AM – 10:00 AM | Welcome and sponsor thank yous

  • Welcome: Deb Spencer (ARC West London)
  • Opening Address: Prof Tony Sedgwick & Graham Combe

10:00 AM – 10:45 AM | Opening Keynote Panel: The Future Promise of Quantum & Deep Tech in Healthcare

· Adam Hammond, Head of Quantum EMEA, IBM

· Anshu Bansal, Imperial College and London Quantum Cluster

· Sonali Mohapatra, National Quantum Computing Centre.

· James Fry, Mills & Reeve

10.45 AM - 11.30 am : De-Risking Pipelines — Target Engagement & New Approach Methodologies (NAMs) and Biomarker Strategies

Unpacking intracellular target engagement in live cells (e.g., CETSA® and biophysical mass spectrometry) alongside microphysiological systems (organ-on-a-chip, 3D organoids) to confirm compound binding and improve translational success before clinical entry. What are the biomarkers we need to look for to find efficacy?

Michael Dabrowski, CEO, Pelago Bioscience AB

Pelin Candorlioglu, 3 D and 3Rs

Michelle Barnard, Valirx plc

Sharon Robinson, DLRC Regulatory Consulting

Prof Christopher Peters, Imperial College

Atefeh Mobasseri, CN Bio


11:30 PM – 12:00 PM | Refreshments & Networking Break

12:00 PM – 12:30 PM | Considerations with IP when using new technologies

Emily Howard, J A Kemp

Flick Kendrick, JA Kemp


12:30 PM – 1.00 PM | Fireside Keynote Interview with Edwin Moses, Chairman, LabGenius, Avantium AV and Nanosyrinx.

1:00 PM – 1:45 PM | Keynote Panel: What’s working so far with AI, and what’s not?

Jeremy Reffin, AI Research Group, University of Sussex

Steve Lindsay, SFL Technology

Juergen Harter, MatriQx

Catherine Stace, O2h Group

Ting Qin, Sygnature Discovery


01:45 PM – 02:45 PM | Networking Lunch

02:45 PM – 03:30 PM | Boots on the Ground – hearing from emerging company leaders about the technologies changing their work

Winston Hayes, LabGenius

Paul Rouse, IMU Biosciences

Chris Tame, Ternary Tx

Hugh O’Brien, LIR Tx

Andrea Dimitracopoulos, Deep Mirror


03:30 PM – 04:10 PM | What are the major early considerations when translating and innovation from promise to idea?

Mariana Vashetto, CDD Vault

Luis Lopez-Navas, DLRC Regulatory Consulting

Isra Salim, Causaly

Ajay Karandikar, Omnitheia


04.10 PM – 04.30 PM | Executive Summary of the day

04:30 PM – 08:30 PM | Champagne Evening Reception

Champagne drinks reception and evening keynote designed to build lasting partnerships across the tech, healthcare, and life sciences ecosystem.

We promise that our #CreativeDisruption Forum will be like no other life sciences event or business network you have experienced. You will be walking out of the session inspired, educated and more connected.

ADMISSION FEE for Service Companies such as CROs, CDMOs, Law Firms and Patent Attorneys, Consultancy Firms = £150 - ALL-INCLUSIVE

ADMISSION FEE for Innovative Emerging Life Science Companies and Independent Consultants = £80

Investors can apply for free entry by writing to graham@biosell.co.uk.


Good to know

Highlights

  • 11 hours
  • In-person

Refund Policy

Refunds up to 2 days before the event

Location

ARC West London

Manbre Road

London W6 9RH

How do you want to get there?

Map
Organised by
Report this event

More events from Graham Combe

Discover more events from Graham Combe, from Science & Tech to other experiences you might love.

Still looking for the right event?

Explore all events in London and filter by date, category, and more to find the perfect fit.